The role and mechanism of hsa-miR-199a/b-3p in the occurrence and development of liver fibrosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900027974

Enrollment

Unknown

Registered

2019-12-07

Start date

2020-01-01

Completion date

Unknown

Last updated

2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

Liver fibrosis group:None

Healthy control group:None

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. All patients accept liver biopsy and the pathological diagnosis is liver fibrosis. 2. Patients >= 18 years of age. 3. All the patients in the group are registered with detailed clinical information such as HBV-DNA level, liver function, and history of drinking alcohol, etc..

Exclusion criteria

Exclusion criteria: 1. There is severe uncontrollable infection; 2. Have a history of severe gastrointestinal diseases, renal dysfunction, heart disease and other organs; 3. The patient currently has other organ diseases that may affect the evaluation of this study; 4. Tumors in any part including the liver; 5. Patients who have undergone liver transplantation; 6. Patients who have undergone liver surgery; 7. Patients with systemic immune system disease.

Design outcomes

Primary

Measure	Time frame
microRNA;	—

Secondary

Measure	Time frame
liver function;Four items of liver fibrosis;Blood routine;	—

Countries

China

Contacts

Public ContactWenlin Tai

Department of Laboratory Medicine, the Second Affiliated Hospital of Kunming Medical University

2820582685@qq.com+86 13619648123

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026